Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Brigham and Women's Hospital
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07417618CT.gov INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD) | — | Active Not Recruiting | — | — | — |
NCT06779929CT.gov Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes | — | Completed | — | — | — |
NCT07096063CT.gov Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk | — | Completed | — | — | — |
NCT05140694CT.gov Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D | — | Unknown | — | — | — |
NCT05005741CT.gov The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity. | — | Unknown | — | — | — |
NCT04829903CT.gov Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin | — | Completed | — | — | — |
NCT03648554CT.gov Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST) | — | Unknown | — | — | — |
NCT00630825CT.gov A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Type 2 Diabetes Mellitus
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dulaglutide (this asset) | Brigham and Women's Hospital | Approved | BB · 64 |
| Liraglutide | RenJi Hospital | P4 | BBB |
| Dapagliflozin | Bhavya Bhavya, MD | P4 | BBB |
| Semaglutide | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Exenatide | Vivani Medical, Inc | P4 | BBB |
| Cotadutide | AstraZeneca | P2 | BBB |
| Metformin | Myopharm Limited | P4 | BBB |
| Saxagliptin | Nick Giannoukakis, PhD | P4 | BBB |
| Midazolam | Pfizer | P4 | BBB |
+41 more in the Type 2 Diabetes Mellitus cohort
Other indications for Dulaglutide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Glucose Intolerance | — | P4 | BBB · 75 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P4 | BB · 65 |
| Hyperglycemia | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dulaglutide in Type 2 Diabetes Mellitus. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dulaglutide-type-2-diabetes-mellitus
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →